Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival; however, relapses are common. A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Ishani, Wilhelm, Margareta, Höiom, Veronica, Franco Marquez, Rodolfo, Costa Svedman, Fernanda, Hansson, Johan, Tuominen, Rainer, Egyhàzi Brage, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737096/
https://www.ncbi.nlm.nih.gov/pubmed/31506424
http://dx.doi.org/10.1038/s41419-019-1875-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737096/
https://www.ncbi.nlm.nih.gov/pubmed/31506424
http://dx.doi.org/10.1038/s41419-019-1875-8

Ejemplares similares